Cybin announces closing of offering of units led by one of the company's largest institutional shareholders

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that it has closed its previously announced underwritten offering (the “offering”). in connection with the offering, the company issued an aggregate of 66,666,667 units of the company (the “units”) at a price.
CYBN Ratings Summary
CYBN Quant Ranking